Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.
Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.
CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
AbbVie announced positive top-line data from the company’s Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate-to-severe rheumatoid arthritis.
An independent committee concluded that Inctye Corp.’s drug for a type of skin cancer in combination with Merck & Co.’s Keytruda failed to meet the main goal in a late-stage study.
As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.
Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).
Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.
Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
Heron Therapeutics said the company’s late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain.
Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.
Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.
The world’s largest diabetes drugmaker, Novo Nordisk, presented the first successful data from a large final-stage study of a pill the company hopes will transform the diabetes market.
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.
Eli Lilly and its Korean collaborative partner Hanmi Pharmaceutical stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined.
Eisai’s Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.